Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase.

  title={Enhanced macrophage uptake of synthetically glycosylated human placental beta-glucocerebrosidase.},
  author={Thomas W. Doebber and M. S. Wu and Robert L. Bugianesi and Mitree M. Ponpipom and F S Furbish and John A. Barranger and Roscoe O. Brady and Tsung Ying Shen},
  journal={The Journal of biological chemistry},
  volume={257 5},
  • T. DoebberM. Wu T. Shen
  • Published 10 March 1982
  • Biology, Chemistry
  • The Journal of biological chemistry

Figures from this paper

Uptake of Mannose-Terminal Glucocerebrosidase in Cultured Human Cholinergic and Dopaminergic Neuron Cell Lines

Mannose-terminal glucocerebrosidase was taken up by cholinergic LA-N-2 cells, but to a much lower extent than by macrophages, and considerably less of the enzyme was endocytosed by dopaminergic SH-SY5Y cells, and it was not taking up by NHA astrocytes.

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Intravenous administration of macrophage-targeted glucocerebrosidase produces objective clinical improvement in patients with type 1 Gaucher's disease.

Failure of Alglucerase Infused into Gaucher Disease Patients to Localize in Marrow Macrophages

Even with the large bolus doses used for the treatment of Gaucher disease by some, scarcely any β-glucosidase activity was found in marrow samples; the amount of the enzyme was much less than would have been anticipated had the enzyme been evenly distributed to all body cells.

Saccharide Receptor-Mediated Drug Delivery

Carohydrate-mediated endocytosis in mammals has since become the subject of intensive studies and macrophages and Kupffer cells have been shown to bind glycoproteins and synthetic neoglycoconjugates that have D-mannose and 2-acetamido-2-deoxy-D-glucose in the exposed non-reducing position.

Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes

This study suggests that further insight in targeting and efficacy of enzyme therapy of individual Gaucher patients could be obtained by the use of recombinant GBA, trace-labeled with an ABP, preferably equipped with an infrared fluorophore or other reporter tag suitable for in vivo imaging.

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.

The production of a recombinant human GCD in a carrot cell suspension culture shows a level of biological activity similar to that of Cerezyme produced in CHO cells, as well as a highly homologous high-resolution three-dimensional structure, determined by X-ray crystallography, indicating the potential safety of prGCD.